$heff's $tation of $tocks & $olid DD

[investor911]

SVA ( UP 24%) - Sinovac Receives China's First Influenza A (H1N1) Vaccine Order

Sinovac Receives China's First Influenza A (H1N1) Vaccine Order

BEIJING, June 19, 2009 /PRNewswire-Asia via COMTEX/ -- Sinovac Biotech Ltd. (NYSE
Amex: SVA), a leading developer and provider of vaccines in China, announced
today that the Company received the first order in China to supply its influenza
A (H1N1) vaccine to the Beijing government. The initial order consists of 4
million doses and is expected to be delivered by the end of September. This order
will be administered to 2 million people in the high risk group. Additional
orders are expected beginning in October and, in total, Sinovac expects to supply
approximately 10 million doses to the Beijing government. The 10 million doses
will be administered to 5 million people in Beijing.

On June 14, 2009, Sinovac completed construction of the H1N1 virus seed bank
necessary to produce a virus antigen and commenced production of the first batch
of H1N1 vaccine. Sinovac expects to complete production of the first batch by the
end of July.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "We are
organizing and coordinating all personnel and resources to produce the H1N1
vaccine, as we have almost completed the production of our seasonal influenza
vaccine. With the support and instruction of the relevant government and health
authorities, Sinovac will fully utilize its proven development and production
abilities from both the H5N1 vaccine and seasonal flu vaccine to ensure the
efficient production of the H1N1 vaccine. We are working closely with authorities
in order to contribute to the prevention and control of the H1N1 epidemic
situation."

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on
the research, development, manufacture and commercialization of vaccines that
protect against human infectious diseases. Sinovac's vaccine products include
Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R)
(influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already
been approved for government stockpiling. Sinovac is developing vaccines for
enterovirus 71, universal pandemic influenza, Japanese encephalitis vaccine, and
human rabies vaccine. Its wholly owned subsidiary, Tangshan Yian, is conducting
field trials for independently developed inactivated animal rabies vaccines.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made
under the "safe harbor" provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements can be identified by words
or phrases such as "will," "expects," "anticipates," "future," "intends,"
"plans," "believes," "estimates" and similar statements. Among other things, the
business outlook and quotations from management in this press release contain
forward-looking statements. Statements that are not historical facts, including
statements about Sinovac's beliefs and expectations, are forward-looking
statements. Forward-looking statements involve inherent risks and uncertainties.
A number of important factors could cause actual results to differ materially
from those contained in any forward-looking statement. Sinovac does not undertake
any obligation to update any forward-looking statement, except as required under
applicable law.

For more information, please contact:

Helen G. Yang
Sinovac Biotech Ltd.
Tel:[phone] x9871
Fax:[phone]
Email: [e-mail]

Investors:
Amy Glynn/Sara Pellegrino
The Ruth Group
Tel:[phone]
Email: [e-mail]
[e-mail]

Media:
Janine McCargo
The Ruth Group
Tel:[phone]
Email: [e-mail]



SOURCE Sinovac Biotech Ltd.

Copyright (C) 2009 PR Newswire. All rights reserved